Search

Your search keyword '"Lluís Tárraga"' showing total 181 results

Search Constraints

Start Over You searched for: Author "Lluís Tárraga" Remove constraint Author: "Lluís Tárraga"
181 results on '"Lluís Tárraga"'

Search Results

1. Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort

2. Changes in choroidal thickness quantified by Optical Coherence Tomography across cognitive impairment: data from the NORFACE cohort

Catalog

Books, media, physical & digital resources

3. Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinicResearch in context

4. Genome-wide association study and polygenic risk scores of retinal thickness across the cognitive continuum: data from the NORFACE cohort

5. Macular vessel density in the superficial plexus is not a proxy of cerebrovascular damage in non-demented individuals: data from the NORFACE cohort

6. Unveiling the sound of the cognitive status: Machine Learning-based speech analysis in the Alzheimer’s disease spectrum

7. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress

8. Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment

9. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline

10. Harnessing acoustic speech parameters to decipher amyloid status in individuals with mild cognitive impairment

11. Differences in macular vessel density in the superficial plexus across cognitive impairment: the NORFACE cohort

12. Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort

13. Macular vessel density in the superficial plexus is not associated to cerebrospinal fluid core biomarkers for Alzheimer’s disease in individuals with mild cognitive impairment: The NORFACE cohort

14. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

15. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

16. The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

17. Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis

18. Early detection of amyloid load using 18F-florbetaben PET

19. Long runs of homozygosity are associated with Alzheimer’s disease

20. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative

21. Neuropsychiatric Profile as a Predictor of Cognitive Decline in Mild Cognitive Impairment

22. Visual impairment in aging and cognitive decline: experience in a Memory Clinic

23. The MAPT H1 Haplotype Is a Risk Factor for Alzheimer’s Disease in APOE ε4 Non-carriers

24. Author Correction: Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic

26. Correction: Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates.

27. Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis.

28. Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates.

29. Cut-off scores of a brief neuropsychological battery (NBACE) for Spanish individual adults older than 44 years old.

30. Sex, Neuropsychiatric Profiles, and Caregiver Burden in Alzheimer’s Disease Dementia: A Latent Class Analysis

31. BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols

32. Identification of undiagnosed dementia cases using a web-based pre-screening tool: The MOPEAD project

33. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline

34. From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery

35. Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort

36. Managing Clinical Trials for Alzheimer’s Disease During the COVID-19 Crisis: Experience at Fundació ACE in Barcelona, Spain

37. Dementia Care in Times of COVID-19: Experience at Fundació ACE in Barcelona, Spain

38. Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative

39. Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort

40. The Synergic Effect of AT(N) Profiles and Depression on the Risk of Conversion to Dementia in Patients with Mild Cognitive Impairment

41. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

42. The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

43. Early detection of amyloid load using 18F-florbetaben PET

44. Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis

45. Long runs of homozygosity are associated with Alzheimer's disease

46. Author Correction: Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic

47. Additional file 6 of The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

48. Additional file 4 of The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

49. Additional file 5 of The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening

50. Additional file 2 of Early detection of amyloid load using 18F-florbetaben PET